Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Pierre Fabre Medicament
Sponsor

Pierre Fabre Medicament

France Les Cauquillous, 81500, France

About the sponsor

Research activity includes locally advanced and metastatic non-small cell lung cancer, with interest in tumors driven by EGFR tyrosine kinase inhibitor resistance as well as cancers carrying BRAF and/or NRAS mutations.

  • Non-small cell lung cancer
  • EGFR-resistant disease
  • BRAF and NRAS mutation-positive tumors
  • Advanced solid tumors

The portfolio also covers investigational oral anticancer agents for molecularly defined cancer subgroups.

About Specializations

Pierre Fabre Medicament runs clinical trials in conditions such as Non-small cell lung cancer metastatic, Epstein-Barr virus associated lymphoproliferative disorder, Neoplasm, Post transplant lymphoproliferative disorder, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

6 clinical trials

Neoplasm+1

Recruiting

Study on the Safety and Effects of VERT-002 for Patients with Advanced Solid Tumors, Including Lung Cancer with MET Alterations

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:VERT-002
  • Sponsor:Pierre Fabre Medicament

Non-small cell lung cancer metastatic

Recruiting

Study on the Safety and Effects of STX-241 for Patients with Advanced Non-Small Cell Lung Cancer Resistant to EGFR Inhibitors

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:STX-241
  • Sponsor:Pierre Fabre Medicament

Post transplant lymphoproliferative disorder+1

Recruiting

Study of Tabelecleucel for Patients with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Transplant Treatment Failure

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tabelecleucel
  • Sponsor:Pierre Fabre Medicament

Epstein-Barr virus associated lymphoproliferative disorder

Recruiting

Study on Tabelecleucel for Patients with Epstein-Barr Virus-Associated Diseases

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Tabelecleucel
  • Sponsor:Pierre Fabre Medicament

Congenital ectodermal dysplasia

Recruiting

Study on ER004 for Treating Boys with X-linked Hypohidrotic Ectodermal Dysplasia (XLHED)

InvestigationalNo placebo
Countries:FranceFrance
  • Substances:Human Immunoglobulin G1 Constant Region - Human Ectodysplasin-A1 Receptor-Binding Domain Fusion Protein
  • Sponsor:Fondation EspeRare

Ex-tobacco user

Not recruiting

Study on the Effects of Nicotine Resinate Lozenge on Cravings in Moderate Smokers in Non-Smoking Situations

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Nicotine Resinate
  • Sponsor:Pierre Fabre Medicament

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.